CAMB 637 - Gene Therapy:Vectors,Immunology and Disease

Institution:
University of Pennsylvania
Subject:
Description:
Chen, Albelda, Bushman, Paterson, Riley, Stedman, Weiner, Wilson, Wolfe, and Xiao. Prerequisite(s): Background in molecular biology, virology and immunology. This seminar course is designed to provide students with a cohesive understanding of virology and immunology of gene therapy. Three major themes will be covered: vectors, vector immunology and gene therapy of genetic and acquired diseases. The topics to be covered are viewed as an extension of topics covered in CAMB 610 (Molecular Basis of Gene Therapy), although CAMB 610 is not an absolute prerequisite for this seminar. Each class will consist of a brief introduction by an instructor, reviewing background information related to the theme discussion. The topics are explored through discussions, led by faculty, of seminal research articles. Students are expected to have thoroughly reviewed the assigned articles and be able to present and discuss various aspects of the papers. Regular attendance and active participation in the discussions, which focus on critical evaluation of experimental design, data presentation and interpretation, is essential. Student evaluation will be based on attendance, preparation, and in-class participation.
Credits:
3.00
Credit Hours:
Prerequisites:
Corequisites:
Exclusions:
Level:
Instructional Type:
Lecture
Notes:
Additional Information:
Historical Version(s):
Institution Website:
Phone Number:
(215) 898-5000
Regional Accreditation:
Middle States Association of Colleges and Schools
Calendar System:
Semester

The Course Profile information is provided and updated by third parties including the respective institutions. While the institutions are able to update their information at any time, the information is not independently validated, and no party associated with this website can accept responsibility for its accuracy.

Detail Course Description Information on CollegeTransfer.Net

Copyright 2006 - 2025 AcademyOne, Inc.